284 related articles for article (PubMed ID: 21543548)
41. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
Hoogendoorn M; Welsing P; Rutten-van Mölken MP
Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
[TBL] [Abstract][Full Text] [Related]
42. Sibutramine for weight gain attenuation during smoking cessation with varenicline: a pilot study.
Sood A; Ebbert JO; Clark MM; Croghan IT; Schroeder DR; Hays JT
Nicotine Tob Res; 2009 Dec; 11(12):1479-84. PubMed ID: 19884116
[TBL] [Abstract][Full Text] [Related]
43. [Varenicline--a new chance for smokers?].
Goniewicz ML; Koszowski B; Czogała J; Sobczak A
Przegl Lek; 2007; 64(10):899-902. PubMed ID: 18409337
[TBL] [Abstract][Full Text] [Related]
44. Over-the-counter availability of nicotine replacement therapy and smoking cessation.
Hyland A; Rezaishiraz H; Giovino G; Bauer JE; Michael Cummings K
Nicotine Tob Res; 2005 Aug; 7(4):547-55. PubMed ID: 16085526
[TBL] [Abstract][Full Text] [Related]
45. Changes in health-related quality of life with smoking cessation treatment.
Hays JT; Croghan IT; Baker CL; Cappelleri JC; Bushmakin AG
Eur J Public Health; 2012 Apr; 22(2):224-9. PubMed ID: 20884658
[TBL] [Abstract][Full Text] [Related]
46. Comparative Effectiveness of Smoking Cessation Medications: A National Prospective Cohort From Taiwan.
Chang PY; Lo PC; Chang HC; Hsueh KC; Tsai YW
PLoS One; 2016; 11(11):e0166992. PubMed ID: 27893843
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
[TBL] [Abstract][Full Text] [Related]
48. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness.
Stapleton JA; Watson L; Spirling LI; Smith R; Milbrandt A; Ratcliffe M; Sutherland G
Addiction; 2008 Jan; 103(1):146-54. PubMed ID: 18028247
[TBL] [Abstract][Full Text] [Related]
49. Impact of an electronic alert and order set on smoking cessation medication prescription.
Mathias JS; Didwania AK; Baker DW
Nicotine Tob Res; 2012 Jun; 14(6):674-81. PubMed ID: 22180576
[TBL] [Abstract][Full Text] [Related]
50. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
[TBL] [Abstract][Full Text] [Related]
51. Characterising the use of varenicline: an analysis of the Australian dispensing claims data.
Gobarani RK; Ilomäki J; Wood S; Abramson MJ; Bonevski B; George J
Addiction; 2022 Oct; 117(10):2683-2694. PubMed ID: 35603915
[TBL] [Abstract][Full Text] [Related]
52. Prevalence of use and real-world effectiveness of smoking cessation aids during the COVID-19 pandemic: a representative study of smokers in England.
Jackson SE; Cox S; Shahab L; Brown J
Addiction; 2022 Sep; 117(9):2504-2514. PubMed ID: 35491743
[TBL] [Abstract][Full Text] [Related]
53. Smoking cessation and varenicline. Do not expose or re-expose patients to its serious adverse effects!
Prescrire Int; 2014 Sep; 23(152):208. PubMed ID: 25325119
[No Abstract] [Full Text] [Related]
54. Effectiveness of coadministration of varenicline, bupropion, and serotonin reuptake inhibitors in a smoking cessation program in the real-life setting.
Issa JS; Abe TO; Moura S; Santos PC; Pereira AC
Nicotine Tob Res; 2013 Jun; 15(6):1146-50. PubMed ID: 23128516
[TBL] [Abstract][Full Text] [Related]
55. Smoking cessation treatment for COPD smokers: the role of pharmacological interventions.
Jiménez-Ruiz CA; Fagerström KO
Monaldi Arch Chest Dis; 2013 Mar; 79(1):27-32. PubMed ID: 23741943
[TBL] [Abstract][Full Text] [Related]
56. Smoking cessation therapy considerations for patients with chronic kidney disease.
Manley HJ; Stack NM
Nephrol Nurs J; 2008; 35(4):357-63, 394; quiz 364. PubMed ID: 18782998
[TBL] [Abstract][Full Text] [Related]
57. Smoking cessation interventions: a primer for physicians: Comment on "Use of varenicline for 4 weeks before quitting smoking".
Simon JA
Arch Intern Med; 2011 Apr; 171(8):777-8. PubMed ID: 21518947
[No Abstract] [Full Text] [Related]
58. Clinical experience of varenicline for smoking cessation.
Jung JW; Jeon EJ; Kim JG; Yang SY; Choi JC; Shin JW; Park IW; Choi BW; Kim DK; Kim JY
Clin Respir J; 2010 Oct; 4(4):215-21. PubMed ID: 20887344
[TBL] [Abstract][Full Text] [Related]
59. Use of varenicline and nicotine replacement therapy in people with and without general practitioner-recorded dementia: retrospective cohort study of routine electronic medical records.
Itani T; Martin R; Rai D; Jones T; Taylor G; Thomas K; Munafo M; Davies N; Taylor A
BMJ Open; 2019 Aug; 9(8):e027569. PubMed ID: 31473613
[TBL] [Abstract][Full Text] [Related]
60. Characteristics and abstinence outcomes among tobacco quitline enrollees using varenicline or nicotine replacement therapy.
Biazzo LL; Froshaug DB; Harwell TS; Beck HN; Haugland C; Campbell SL; Helgerson SD
Nicotine Tob Res; 2010 Jun; 12(6):567-73. PubMed ID: 20378640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
